Lerche, S;
Wurster, I;
Röben, B;
Machetanz, G;
Zimmermann, M;
Bernhard, F;
Stransky, E;
... Brockmann, K; + view all
(2019)
Parkinson’s disease: evolution of cognitive impairment and CSF Aβ₁−₄₂ profiles in a prospective longitudinal study.
Journal of Neurology, Neurosurgery and Psychiatry
, 90
(2)
pp. 165-170.
10.1136/jnnp-2018-318956.
Preview |
Text
Zetterberg_Parkinson's disease. Evolution of cognitive impairment and CSF Aβ₁−₄₂ profiles in a prospective longitudinal study_AAM.pdf - Accepted Version Download (692kB) | Preview |
Abstract
OBJECTIVE: To evaluate the evolution of cognitive impairment in relation to cerebrospinal fluid (CSF) profiles of amyloid-β (Aβ), total-Tau and phosphorylated-Tau in Parkinson’s disease (PD). METHODS: Prospective, longitudinal, observational study up to 10 years with follow-up every 2 years. We assessed CSF profiles in 415 patients with sporadic PD (median age 66; 63% men) and 142 healthy controls (median age 62; 43% men). RESULTS: Patients with PD with low CSF Aβ₁−₄₂ levels at baseline were more often cognitively impaired than patients with intermediate and high Aβ₁−₄₂ levels. Sixty-seven per cent of the patients with low Aβ₁−₄₂ levels at baseline and normal cognition developed cognitive impairment during follow-up, compared with 41% and 37% of patients having intermediate and high CSF Aβ₁−₄₂ levels. Kaplan-Meier survival curves and Cox regression revealed that patients with low CSF Aβ₁−₄₂ levels at baseline developed cognitive impairment more frequently and earlier during follow-up. CONCLUSION: We conclude that in patients with sporadic PD, low levels of Aβ₁−₄₂ are associated with a higher risk of developing cognitive impairment earlier in the disease process at least in a subgroup of patients.
Archive Staff Only
 |
View Item |
